A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Clinical trial NCT01130519 · COMPLETED
Trial details
- NCT number
- NCT01130519
- Sponsor
- National Cancer Institute (NCI)
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2010-05-06
- Primary completion
- 2022-04-12
- Enrollment
- 83
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.